LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 512

Search options

  1. Book: Pocket Cardiology

    Sabatine, Marc S.

    (Biopsy Interpretation Series)

    2022  

    Series title Biopsy Interpretation Series
    Keywords cardiac arrhythmia ; pulmonary medicine ; genetic medicine ; genetics in medicine ; acls american heart ; cardiology review ; braunwald's heart disease ; braunwald s heart disease ; goldman-cecil medicine ; family medicine textbook ; medicine morning report ; davidson medicine ; family medicine handbook ; ettinger veterinary internal medicine ; goldberger's clinical electrocardiography ; goldbergers clinical electrocardiography ; sanford guide pocket ; zipes electrophysiology ; current internal ; pockets notebook
    Language English
    Size 280 p.
    Edition 2
    Publisher Lippincott Williams
    Document type Book
    Note PDA Manuell_15
    Format 121 x 187 x 22
    ISBN 9781975106133 ; 197510613X
    Database PDA

    Kategorien

  2. Book: Cardiovascular therapeutics

    Antman, Elliott M. / Sabatine, Marc S.

    a companion to Braunwald's heart disease

    (Expert consult)

    2013  

    Author's details Elliott M. Antman ; Marc S. Sabatine
    Series title Expert consult
    Keywords Cardiovascular Diseases / therapy
    Language English
    Size XXI, 807 S. : Ill., graph. Darst.
    Edition 4. ed.
    Publisher Elsevier Saunders
    Publishing place Philadelphia, Pa
    Publishing country United States
    Document type Book
    Note Includes bibliographical references and index
    Accompanying material Zugang zur Internetausgabe über Code
    HBZ-ID HT017398934
    ISBN 978-1-4557-0101-8 ; 1-4557-0101-7
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  3. Article ; Online: Differentiating Type 1 and Type 2 Myocardial Infarction: Unfortunately, Still More Art Than Science.

    Sabatine, Marc S

    JAMA cardiology

    2021  Volume 6, Issue 7, Page(s) 781

    MeSH term(s) Humans ; Myocardial Infarction/diagnosis ; Myocardial Infarction/epidemiology ; Myocardial Infarction/therapy
    Language English
    Publishing date 2021-04-21
    Publishing country United States
    Document type Editorial ; Comment
    ISSN 2380-6591
    ISSN (online) 2380-6591
    DOI 10.1001/jamacardio.2021.0693
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Anticipating Pharmacological Perturbation With Human Genetic Variation-Lessons From CETP.

    Natarajan, Pradeep / Sabatine, Marc S

    JAMA cardiology

    2022  Volume 7, Issue 9, Page(s) 964–965

    MeSH term(s) Cholesterol Ester Transfer Proteins/genetics ; Cholesterol, HDL/genetics ; Genetic Variation ; Humans
    Chemical Substances CETP protein, human ; Cholesterol Ester Transfer Proteins ; Cholesterol, HDL
    Language English
    Publishing date 2022-08-03
    Publishing country United States
    Document type Journal Article
    ISSN 2380-6591
    ISSN (online) 2380-6591
    DOI 10.1001/jamacardio.2022.2342
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: PCSK9 inhibitors: what we know, what we should have understood, and what is to come.

    Sabatine, Marc S

    European heart journal

    2019  Volume 43, Issue 7, Page(s) e29–e31

    Language English
    Publishing date 2019-07-22
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 603098-1
    ISSN 1522-9645 ; 0195-668X
    ISSN (online) 1522-9645
    ISSN 0195-668X
    DOI 10.1093/eurheartj/ehz514
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Pharmacogenetics and the Promise of Personalized Medicine.

    Sabatine, Marc S

    JAMA cardiology

    2018  Volume 3, Issue 5, Page(s) 408

    MeSH term(s) Benzodiazepines ; Case-Control Studies ; Humans ; Pharmacogenetics ; Precision Medicine ; Vascular Diseases
    Chemical Substances Benzodiazepines (12794-10-4) ; evacetrapib (51XWV9K850)
    Language English
    Publishing date 2018-03-07
    Publishing country United States
    Document type Editorial ; Comment
    ISSN 2380-6591
    ISSN (online) 2380-6591
    DOI 10.1001/jamacardio.2018.0586
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: PCSK9 inhibitors: clinical evidence and implementation.

    Sabatine, Marc S

    Nature reviews. Cardiology

    2018  Volume 16, Issue 3, Page(s) 155–165

    Abstract: The gene encoding PCSK9 was first identified and linked to the phenotype of familial hypercholesterolaemia approximately 15 years ago. Soon after, studies uncovered the role of PCSK9 in the regulation of LDL-receptor recycling and identified loss-of- ... ...

    Abstract The gene encoding PCSK9 was first identified and linked to the phenotype of familial hypercholesterolaemia approximately 15 years ago. Soon after, studies uncovered the role of PCSK9 in the regulation of LDL-receptor recycling and identified loss-of-function variants of PCSK9 that were associated with low circulating levels of LDL cholesterol (LDL-C) and a reduced risk of coronary artery disease. With amazing rapidity, monoclonal antibodies against PCSK9 were developed and studied in large clinical programmes. These PCSK9 inhibitors lowered plasma LDL-C levels by approximately 60%, even in patients already receiving maximum-dose statin therapy. In the past year, three cardiovascular outcome trials were completed and showed that PCSK9 inhibitors significantly reduce the risk of major vascular events. Reassuringly, this benefit comes with no major offsetting adverse events, such as an excess of myalgias, elevation of hepatic aminotransferases levels in the plasma, incident diabetes mellitus or neurocognitive adverse events. The clinical benefit of PCSK9 inhibitors seen in these trials occurred in the setting of reducing LDL-C levels to unprecedentedly low levels, suggesting that more aggressive LDL-C targets should be adopted. New technologies to inhibit PCSK9 are now being harnessed and might further revolutionize our treatment of dyslipidaemia.
    MeSH term(s) Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Anticholesteremic Agents/adverse effects ; Anticholesteremic Agents/therapeutic use ; Biomarkers/blood ; Cardiovascular Diseases/blood ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/prevention & control ; Cholesterol, LDL/blood ; Drug Therapy, Combination ; Dyslipidemias/blood ; Dyslipidemias/complications ; Dyslipidemias/drug therapy ; Dyslipidemias/enzymology ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Proprotein Convertase 9/antagonists & inhibitors ; Proprotein Convertase 9/metabolism ; Randomized Controlled Trials as Topic ; Serine Proteinase Inhibitors/adverse effects ; Serine Proteinase Inhibitors/therapeutic use ; Time Factors ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal, Humanized ; Anticholesteremic Agents ; Biomarkers ; Cholesterol, LDL ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Serine Proteinase Inhibitors ; PCSK9 protein, human (EC 3.4.21.-) ; Proprotein Convertase 9 (EC 3.4.21.-) ; evolocumab (LKC0U3A8NJ) ; alirocumab (PP0SHH6V16)
    Language English
    Publishing date 2018-11-12
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2490375-9
    ISSN 1759-5010 ; 1759-5002
    ISSN (online) 1759-5010
    ISSN 1759-5002
    DOI 10.1038/s41569-018-0107-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Thrombolysis In Myocardial Infarction (TIMI) Study Group: JACC Focus Seminar 2/8.

    Sabatine, Marc S / Braunwald, Eugene

    Journal of the American College of Cardiology

    2021  Volume 77, Issue 22, Page(s) 2822–2845

    Abstract: In 1984, the National Heart, Lung, and Blood Institute (NHLBI) decided to study the efficacy and safety of the treatment of acute myocardial infarction with an emerging therapy, coronary thrombolysis, and thus the TIMI (Thrombolysis In Myocardial ... ...

    Abstract In 1984, the National Heart, Lung, and Blood Institute (NHLBI) decided to study the efficacy and safety of the treatment of acute myocardial infarction with an emerging therapy, coronary thrombolysis, and thus the TIMI (Thrombolysis In Myocardial Infarction) Study Group was born. Following completion of 3 clinical trials of thrombolytic therapy supported by the NHLBI, TIMI became an academic research organization headquartered at Brigham and Women's Hospital and subsequently branched out to study a wide range of patients, including those with stable coronary, cerebrovascular, and peripheral arterial disease; dyslipidemia; heart failure; atrial fibrillation; diabetes; and obesity. TIMI also began to study a wide range of interventions including thrombolytic, antithrombotic, lipid-modifying, anti-inflammatory, heart failure, glucose-lowering, and weight loss agents. TIMI, now in its 37th year, has completed >70 trials. This review describes the origins of the TIMI Study Group, summarizes several of its completed trials and the major lessons learned from them, and discusses ongoing trials and future directions.
    MeSH term(s) Cardiology/trends ; Humans ; Myocardial Infarction/therapy ; Thrombolytic Therapy
    Language English
    Publishing date 2021-06-03
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 605507-2
    ISSN 1558-3597 ; 0735-1097
    ISSN (online) 1558-3597
    ISSN 0735-1097
    DOI 10.1016/j.jacc.2021.01.060
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Response by O'Donoghue et al to Letter Regarding Article, "Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease".

    O'Donoghue, Michelle L / Giugliano, Robert P / Sabatine, Marc S

    Circulation

    2023  Volume 147, Issue 16, Page(s) 1258–1259

    MeSH term(s) Humans ; Cardiovascular Diseases/drug therapy ; Atherosclerosis/drug therapy ; Antibodies, Monoclonal, Humanized/therapeutic use ; Patients
    Chemical Substances evolocumab (LKC0U3A8NJ) ; Antibodies, Monoclonal, Humanized
    Language English
    Publishing date 2023-04-17
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 80099-5
    ISSN 1524-4539 ; 0009-7322 ; 0069-4193 ; 0065-8499
    ISSN (online) 1524-4539
    ISSN 0009-7322 ; 0069-4193 ; 0065-8499
    DOI 10.1161/CIRCULATIONAHA.123.064048
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: comparing and contrasting guidance across the Atlantic.

    Sabatine, Marc S

    European heart journal

    2017  Volume 38, Issue 29, Page(s) 2256–2258

    Language English
    Publishing date 2017-01-04
    Publishing country England
    Document type Editorial ; Comment ; Published Erratum
    ZDB-ID 603098-1
    ISSN 1522-9645 ; 0195-668X
    ISSN (online) 1522-9645
    ISSN 0195-668X
    DOI 10.1093/eurheartj/ehw572
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top